Alexander Gutfraind

Prof. Alexander Gutfraind

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
AGAlexander Gutfraind
Alexander Gutfraind
AGAlison P. Galvani
Alison P. Galvani
LMLauren Ancel Meyers
Lauren Ancel Meyers
In the United States, the mortality burden of respiratory syncytial virus (RSV) infection in children younger than 1 year exceeds that of all influenza strains combined,1 and RSV infection is the leading cause of pediatric hospitalizations, resulting in more than 90 000 hospitalizations annually.2 Globally, RSV is estimated to cause an annual 33.8 million severe acute lower respiratory tract infections in children younger than 5 years.3,4 No vaccine protects against RSV, but palivizumab, a humanized monoclonal antibody marketed as Synagis (Medimmune), has been found to reduce hospitalizations by 55% (and as much as 72%) when delivered prophylactically to children at high risk.5-7 Palivizumab prophylaxis has been approved in 83 countries8 and is a primary control strategy for RSV infection worldwide.9 Dosing policies and target groups are similar among developed countries and are based on international clinical trials.5,10 Immunoprophylaxis is recommended for infants born at a gestational age of younger than 29 weeks and infants at risk for RSV-related hospitalization due to hemodynamically significant congenital heart disease, chronic lung disease of prematurity, congenital abnormalities, or lung conditions that compromise the handling of respiratory secretions.11 In the United States, palivizumab is administered by monthly intramuscular injection during the RSV season for a total of up to 5 doses per patient.10 Palivizumab administration is controversial because of its high cost,2,12,13 which exceeded $10 665 for a 5-dose regimen in 201313 and can reach $15 000 for some patients.14 The total annual cost of palivizumab worldwide is estimated to be $1.2 billion,8,15 which is primarily borne by insurance companies and national payers. Although the manufacturer provides some rebates, palivizumab has been the most costly pharmaceutical item in some fiscal quarters of the Medicaid program.16 Consequently, considerable interest exists in improving the effectiveness and reducing the costs of RSV prevention.6,12,17

10 November 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AGAlexander Gutfraind
Alexander Gutfraind
Complex socioeconomic networks such as information, finance and even terrorist networks need resilience to cascades - to prevent the failure of a single node from causing a far-reaching domino effect. We show that terrorist and guerrilla networks are uniquely cascade-resilient while maintaining high efficiency, but they become more vulnerable beyond a certain threshold. We also introduce an optimization method for constructing networks with high passive cascade resilience. The optimal networks are found to be based on cells, where each cell has a star topology. Counterintuitively, we find that there are conditions where networks should not be modified to stop cascades because doing so would come at a disproportionate loss of efficiency. Implementation of these findings can lead to more cascade-resilient networks in many diverse areas.

11 July 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MMMarian Major
Marian Major
AGAlexander Gutfraind
Alexander Gutfraind
LSLouis Shekhtman
Louis Shekhtman
QCQingwen Cui
Qingwen Cui
AKAlla Kachko
Alla Kachko
HDHarel Dahari
Harel Dahari
The major route of hepatitis C virus (HCV) transmission in the United States is injection drug use. We hypothesized that if an HCV vaccine were available, vaccination could affect HCV transmission among people who inject drugs by reducing HCV titers after viral exposure without necessarily achieving sterilizing immunity. To investigate this possibility, we developed a mathematical model to determine transmission probabilities relative to the HCV RNA titers of needle/syringe-sharing donors. We simulated sharing of two types of syringes fitted with needles that retain either large or small amounts of fluid after expulsion. Using previously published viral kinetics data from both naïve subjects infected with HCV and reinfected individuals who had previously cleared an HCV infection, we estimated transmission risk between pairs of serodiscordant injecting drug users, accounting for syringe type, rinsing, and sharing frequency. We calculated that the risk of HCV transmission through syringe sharing increased ~10-fold as viral titers (log10 IU/ml) increased ~25-fold. Cumulative analyses showed that, assuming sharing episodes every 7 days, the mean transmission risk over the first 6 months was >90% between two people sharing syringes when one had an HCV RNA titer >5 log10 IU/ml. For those with preexisting immunity that rapidly controlled HCV, the cumulative risk decreased to 1 to 25% depending on HCV titer and syringe type. Our modeling approach demonstrates that, even with transient viral replication after exposure during injection drug use, HCV transmission among people sharing syringes could be reduced through vaccination if an HCV vaccine were available.

1 July 2019 in European Journal of Operational Research
Verified
Journal Article
Open access
VBVicki Bier
Vicki Bier
AGAlexander Gutfraind
Alexander Gutfraind

30 September 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AGAlexander Gutfraind
Alexander Gutfraind
BBBasmattee Boodram
Basmattee Boodram
NPNikhil Prachand
Nikhil Prachand
AHAtesmachew Hailegiorgis
Atesmachew Hailegiorgis
HDHarel Dahari
Harel Dahari
MMMarian E. Major
Marian E. Major
People who inject drugs (PWID) are at high risk for blood-borne pathogens transmitted during the sharing of contaminated injection equipment, particularly hepatitis C virus (HCV). HCV prevalence is influenced by a complex interplay of drug-use behaviors, social networks, and geography, as well as the availability of interventions, such as needle exchange programs. To adequately address this complexity in HCV epidemic forecasting, we have developed a computational model, the Agent-based Pathogen Kinetics model (APK). APK simulates the PWID population in metropolitan Chicago, including the social interactions that result in HCV infection. We used multiple empirical data sources on Chicago PWID to build a spatial distribution of an in silico PWID population and modeled networks among the PWID by considering the geography of the city and its suburbs. APK was validated against 2012 empirical data (the latest available) and shown to agree with network and epidemiological surveys to within 1%. For the period 2010–2020, APK forecasts a decline in HCV prevalence of 0.8% per year from 44(±2)% to 36(±5)%, although some sub-populations would continue to have relatively high prevalence, including Non-Hispanic Blacks, 48(±5)%. The rate of decline will be lowest in Non-Hispanic Whites and we find, in a reversal of historical trends, that incidence among non-Hispanic Whites would exceed incidence among Non-Hispanic Blacks (0.66 per 100 per years vs 0.17 per 100 person years). APK also forecasts an increase in PWID mean age from 35(±1) to 40(±2) with a corresponding increase from 59(±2)% to 80(±6)% in the proportion of the population >30 years old. Our studies highlight the importance of analyzing subpopulations in disease predictions, the utility of computer simulation for analyzing demographic and health trends among PWID and serve as a tool for guiding intervention and prevention strategies in Chicago, and other major cities.

1 October 2012 in Journal of the Operational Research Society
Verified
Journal Article
Closed access
MAM P Atkinson
M P Atkinson
AGAlexander Gutfraind
Alexander Gutfraind
MKM Kress
M Kress
Major revolts have recently erupted in parts of the Middle East with substantial international repercussions. Predicting, coping with and winning those revolts have become a grave problem for many regimes and for world powers. We propose a new model of such revolts that describes their evolution by building on the classic Lanchester theory of combat. The model accounts for the split in the population between those loyal to the regime and those favouring the rebels. We show that, contrary to classical Lanchesterian insights regarding traditional force-on-force engagements, the outcome of a revolt is independent of the initial force sizes; it only depends on the fraction of the population supporting each side and their combat effectiveness. The model's predictions are consistent with the situations currently observed in Afghanistan, Libya and Syria (September 2011), and it points to how those situations might evolve.